Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary...

Full description

Bibliographic Details
Main Authors: S. Morteza Seyed Jafari, Laurence Feldmeyer, Simon Bossart, Dagmar Simon, Christoph Schlapbach, Luca Borradori
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Immunology
Subjects:
bullous pemphigoid
dupilumab
omalizumab
recalcitrant
treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.611549/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.611549/full

Similar Items